Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease

Pombiliti™ + Opfolda™ Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus Therapeutics to Host Conference...

Related Keywords

United States ,Philadelphia ,Pennsylvania ,United Kingdom ,Andrew Faughnan ,Priya Kishnani ,Diana Moore ,Johnf Crowley ,Bradley Campbell ,Tahseen Mozaffar ,Department Of Neurology ,Exchange Commission ,Linkedin ,Globenewswire Inc ,Amicus Therapeutics Inc ,Maltase Deficiency Association ,Team Amicu ,Global Corporate Communications ,Amicus Therapeutics ,Neuromuscular Center ,Duke University School Of Medicine ,European Union ,School Of Medicine ,Drug Administration ,Twitter ,Division Of Neuromuscular Diseases ,Only Two Component Therapy ,Eligible Adults Living ,Late Onset Pompe Disease ,Executive Chairman ,Chief Executive Officer ,Neuromuscular Diseases ,Medical Genetics ,University School ,Maltase Deficiency ,Breakthrough Therapy ,Amicus Assist ,Prescribing Information ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Markets ,